Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  O'Sullivan, Ciara C ^a   Moon, Dominic H ^a,b   Kohn, Elise C ^a   Lee, Jung Min ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

BRCA mutation; BRCA like; DNA damage repair pathway; Poly(ADP ribose) polymerase inhibitors; solid tumors

Indexed keywords

BMN 673; CEP 9722; E 7016; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB; UNCLASSIFIED DRUG; VELIPARIB;

APOPTOSIS; BILE DUCT CANCER; BREAST CANCER; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; DNA DAMAGE; ESOPHAGUS CANCER; EWING SARCOMA; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MUTATION; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RECTUM CANCER; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; UROGENITAL TRACT TUMOR; UTERINE CERVIX CANCER;

EID: 84898020932     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00042     Document Type: Review

References (139)

1. Rosen EM, Fan S, Pestell RG, Goldberg ID. BRCA1 gene in breast cancer. J Cell Physiol (2003) 196(1):19-41. doi:10.1002/jcp.10257
2. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 12(3):333-7. doi:10.1038/ng0396-333
3. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 376(9737):245-51. doi:10.1016/S0140-6736(10)60893-8
4. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361(2):123-34. doi:10.1056/NEJMoa0900212
5. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 376(9737):235-44. doi:10.1016/S0140-6736(10)60892-6
6. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 28(15):2512-9. doi:10.1200/JCO.2009.26.9589
7. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol (2012) 30(4):372-9. doi:10.1200/JCO.2011.36.9215
8. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 4(10):814-9. doi:10.1038/nrc1457
9. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin (2011) 61(1):31-49. doi:10.3322/caac.20095
10. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res (2004) 10(3):881-9. doi:10.1158/1078-0432.CCR-1144-3
11. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res (2008) 6(10):1621-9. doi:10.1158/1541-7786
12. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res (2000) 6(7):2860-7.
13. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res (2005) 11(23):8449-57. doi:10.1158/1078-0432.CCR-05-1224
14. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 13(9):2728-37. doi:10.1158/1078-0432.CCR-06-3039
15. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther (2003) 2(4):371-82.
16. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 13(10):3033-42. doi:10.1158/1078-0432.CCR-06-2872
17. Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B. PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys (2004) 58(2):410-9. doi:10.1016/j.ijrobp.2003.09.053
18. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol (2011) 22(2):268-79. doi:10.1093/annonc/mdq322
19. Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem (2012) 19(23):3907-21. doi:10.2174/092986712802002464
20. Weil MK, Chen AP. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 35(1):7-50. doi:10.1016/j.currproblcancer.2010.12.002
21. Plummer R, Middleton M, Wilson R, Jones C, Evans J, Robson L, et al. First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. J Clin Oncol (2005) 23(Suppl 16):abstr3065.
22. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 104(5):750-5. doi:10.1038/bjc.2011.422
23. Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs (2012) 30(4):1493-500. doi:10.1007/s10637-011-9682-9
24. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res (2003) 9(14):5370-9.
25. Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, et al. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol (2012) 7(3):308-22. doi:10.1016/j.molonc.2012.10.002
26. Davidson D, Wang Y, Aloyz R, Panasci L. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Invest New Drugs (2013) 31(2):461-8. doi:10.1007/s10637-012-9886-7
27. Hemel D, Domchek SM. Breast cancer predisposition syndromes. Hematol Oncol Clin North Am (2010) 24(5):799-814. doi:10.1016/j.hoc.2010.06.004
28. Russo A, Calo V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. Crit Rev Oncol Hematol (2009) 69(1):28-44. doi:10.1016/j.critrevonc.2008.06.003
29. Kobayashi H, Ohno S, Sasaki Y, Matsuura M. Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep (2013) 30(3):1019-29. doi:10.3892/or.2013.2541
30. Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res (2013) 19(13):3396-403. doi:10.1158/1078-0432
31. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 94(18):1365-72. doi:10.1093/jnci/94.18.1365
32. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer (2011) 105(8):1230-4. doi:10.1038/bjc.2011.383
33. Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer (2012) 106(10):1697-701. doi:10.1038/bjc.2012.146
34. Marks JL, Golas B, Kirchoff T, Miller VA, Riely GJ, Offit K, et al. EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. J Thorac Oncol (2008) 3(7):805. doi:10.1097/JTO.0b013e31817e4664
35. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature (2001) 411(6835):366-74. doi:10.1038/35077232
36. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res (2002) 511(2):145-78. doi:10.1016/S1383-5742(02)00009-1
37. Ame JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem (1999) 274(25):17860-8. doi:10.1074/jbc.274.25.17860
38. Haince JF, Kozlov S, Dawson VL, Dawson TM, Hendzel MJ, Lavin MF, et al. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem (2007) 282(22):16441-53. doi:10.1074/jbc.M608406200
39. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol (1998) 18(6):3563-71.
40. Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anti- cancer therapy. Expert Rev Anticancer Ther (2010) 10(7):1125-36. doi:10.1586/era.10.53
41. Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, Peralta A, Valenzuela MT, Matinez-Romero R, et al. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition. BMC Mol Biol (2007) 8:29. doi:10.1186/1471-2199-8-29
42. Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J (2009) 28(17):2601-15. doi:10.1038/emboj.2009.206
43. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J (1999) 342(Pt 2):249-68. doi:10.1042/0264-6021:3420249
44. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 108(8):3406-11. doi:10.1073/pnas.1013715108
45. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 26(22):3785-90. doi:10.1200/JCO.2008.16.0812
46. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434(7035):917-21. doi:10.1038/nature03445
47. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 10(4):293-301. doi:10.1038/nrc2812
48. Mansour WY, Rhein T, Dahm-Daphi J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic Acids Res (2010) 38(18):6065-77. doi:10.1093/nar/gkq387
49. Wang M, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res (2006) 34(21):6170-82. doi:10.1093/nar/gkl840
50. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol (2011) 5(4):387-93. doi:10.1016/j.molonc.2011.07.001
51. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res (2012) 72(21):5588-99. doi:10.1158/0008-5472
52. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434(7035):913-7. doi:10.1038/nature03443
53. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 66(16):8109-15. doi:10.1158/0008-5472.CAN-06-0140
54. Gallagher DJ, Konner JA, Bell-McGuinn KM, Bhatia J, Sabbatini P, Aghajanian CA, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol (2011) 22(5):1127-32. doi:10.1093/annonc/mdq577
55. Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R, et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther (2011) 10(10):2000-7. doi:10.1158/1535-7163.MCT-11-0272
56. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 30(21):2654-63. doi:10.1200/JCO.2011.39.8545
57. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res (2006) 8(4):R38. doi:10.1186/bcr1522
58. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 92(7):564-9. doi:10.1093/jnci/92.7.564
59. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res (2005) 65(23):10692-9. doi:10.1158/0008-5472.CAN-05-1277
60. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 115(5):523-35. doi:10.1016/S0092-8674(03)00930-9
61. Long KC, Kauff ND. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Curr Opin Oncol (2011) 23(5):526-30. doi:10.1097/CCO.0b013e3283499da9
62. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 108(44):18032-7. doi:10.1073/pnas.1115052108
63. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474(7353):609-15. doi:10.1038/nature10166
64. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 28(22):3555-61. doi:10.1200/JCO.2009.27.5719
65. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res (1999) 59(1):24-7.
66. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res (2005) 65(2):383-6.
67. Vorechovsky I, Luo L, Ortmann E, Steinmann D, Dork T. Missense mutations at ATM gene and cancer risk. Lancet (1999) 353(9160):1276. doi:10.1016/S0140-6736(05)75199-0
68. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 286(5449):2528-31. doi:10.1126/science.286.5449.2528
69. Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, et al. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer (2002) 33(1):17-21. doi:10.1002/gcc.1207
70. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene (2004) 23(4):1000-4. doi:10.1038/sj.onc.1207256
71. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 64(9):2994-7. doi:10.1158/0008-5472.CAN-04-0245
72. Makridakis NM, Reichardt JK. Translational DNA polymerases and cancer. Front Genet (2012) 3:174. doi:10.3389/fgene.2012.00174.ecollection2012
73. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer (2012) 12(12):801-17. doi:10.1038/nrc3399
74. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 1(6-7):315-22. doi:10.1002/emmm.200900041
75. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 2:53ra75. doi:10.1126/scitranslmed.3001538
76. Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol (2011) 8(5):302-6. doi:10.1038/nrclinonc.2011.42
77. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, et al. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2012) 18(4):1015-27. doi:10.1158/1078-0432.CCR-11-2189
78. Hunt CR, Gupta A, Horikoshi N, Pandita TK. Does PTEN loss impair DNA double-strand break repair by homologous recombination? Clin Cancer Res (2012) 18(4):920-2. doi:10.1158/1078-0432.CCR-11-3131
79. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res (2013) 11(2):140-8. doi:10.1158/1541-7786.MCR-12-0401
80. Cruz C, Teule A, Caminal JM, Blanco I, Piulats JM. Uveal melanoma and BRCA1/BRCA2 genes: a relationship that needs further investigation. J Clin Oncol (2011) 29(34):827-9. doi:10.1200/JCO.2011.37.8828
81. Jang S, Atkins MB. Treatment of BRAF mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther (2013) 95(1):24-31. doi:10.1038/clpt.2013.197
82. Matos AM, Francisco AP. Targets, structures, and recent approaches in malignant melanoma chemotherapy. ChemMedChem (2013) 8:1751-65. doi:10.1002/cmdc.201300248
83. Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA. Novel approaches in melanoma prevention and therapy. Cancer Treat Res (2014) 159:443-55. doi:10.1007/978-3-642-38007-5_25
84. Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA, et al. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol (2011) 29(Suppl):abstr8519.
85. Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, et al. Ipilimumab in advanced melanoma: reports of long-lasting responses. Melanoma Res (2012) 22(3):263-70. doi:10.1097/CMR.0b013e328353e65c
86. Korabiowska M, Konig F, Verheggen R, Schlott T, Cordon-Cardo C, Romeike B, et al. Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases. Anticancer Res (2004) 24(2B):981-6.
87. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, et al. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer (2009) 100(2):322-33. doi:10.1038/sj.bjc.6604856
88. Toshimitsu H, Yoshimoto Y, Augustine CK, Padussis JC, Yoo JS, Angelica Selim M, et al. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol (2010) 17(8):2247-54. doi:10.1038/sj.bjc.6604856
89. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, et al. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest (2009) 27(7):756-63. doi:10.1080/07357900802709159
90. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol (2006) 24:8013. doi:10.1158/1078-0432.CCR-08-1223
91. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, et al. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol (2013) 71(5):1191-9. doi:10.1007/s00280-013-2113-1
92. Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma (2012). Available from: www.clinicaltrials.gov
93. Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination with Temozolomide in Subjects with Advanced Solid Tumors (2013). Available from: www.clinicaltrials.gov
94. Salama AK. Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol (2013) 7:137-49. doi:10.4137/CMO.S9565
95. Habbe N, Langer P, Sina-Frey M, Bartsch DK. Familial pancreatic cancer syndromes. Endocrinol Metab Clin North Am (2006) 35(2):417-30,xi. doi:10.1016/j.ecl.2006.02.016
96. Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst (1999) 91(15):1310-6.
97. Leung K, Saif MW. BRCA-associated pancreatic cancer: the evolving management. JOP (2013) 14(2):149-51. doi:10.6092/1590-8577/1462
98. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst (2011) 103(4):334-46. doi:10.1093/jnci/djq509
99. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: an open-label phase II study. J Clin Oncol (2013) 31(Suppl):abstr11024.
100. Pishvaian M, Wang H, Zhuang T, He A, Hwang J, Hankin A, et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). J Clin Oncol (2013) 30(Suppl 34):abstr147.
101. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet (2003) 72(1):1-12. doi:10.1086/345310
102. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, Olafsdottir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst (2007) 99(12):929-35. doi:10.1093/jnci/djm005
103. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 31(14):1748-57. doi:10.1200/JCO.2012.43.1882
104. Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol (2013) 24(5):1416-8. doi:10.1093/annonc/mdt074
105. Schiewer MJ, Morey LM, Burd CJ, Liu Y, Merry DE, Ho SM, et al. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene (2009) 28(7):1016-27. doi:10.1038/onc.2008.446
106. Tan SH, Furusato B, Fang X, He F, Mohamed AA, Griner NB, et al. Evaluation of ERG responsive proteome in prostate cancer. Prostate (2013) 74(1):70-89. doi:10.1002/pros.22731
107. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 310(5748):644-8. doi:10.1126/science.1117679
108. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 19(5):664-78. doi:10.1016/j.ccr.2011.04.010
109. Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One (2013) 8(4):e60408. doi:10.1371/journal.pone.0060408
110. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 14(9):882-92. doi:10.1016/S1470-2045(13)70240-7
111. TOPARP. A phase II trial of olaparib in patients with advanced castration resistant prostate cancer (2012). Available from: www.clinicaltrials.gov
112. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res (2009) 15(23):7277-90. doi:10.1158/1078-0432.CCR-09-1245
113. Hussain M, Carducci MA, Slovin SF, Jeremy PC, Jiang Q, McKeegan EM, et al. Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol (2012) 30(Suppl 5):abstr224.
114. Miquel C, Jacob S, Grandjouan S, Aime A, Viguier J, Sabourin JC, et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene (2007) 26(40):5919-26. doi:10.1038/sj.onc.1210419
115. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 71(7):2632-42. doi:10.1158/0008-5472.CAN-10-1120
116. Takahashi M, Koi M, Balaguer F, Boland CR, Goel A. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem (2011) 286(14):12157-65. doi:10.1074/jbc.M110.198804
117. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther (2007) 6(3):945-56. doi:10.1158/1535-7163.MCT-06-0552
118. Leichman LP, Cohen SJ, Hochster HS, Messersmith WA, Lenz H, Boman BM, et al. A phase II trial to assess the single-agent efficacy and safety of the PARP inhibitor olaparib (O) in previously treated patients (pts) with metastatic, measurable colorectal cancer (mCRC) stratified by microsatellite status (MSs). Presented at 2010 Molecular Markers Meeting. Hollywood, FL (2012). Available from: http://meetinglibrary.asco.org/content/60883-101
119. Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, Wang L, et al. In vitro and in vivo enhancement of chemoradiation using the oral parp inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys (2013) 86(3):469-76. doi:10.1016/j.ijrobp.2013.02.015
120. Pishvaian MJ, Slack R, Witkiewicz A, He AR, Hwang JJ, Hankin A, et al. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. J Clin Oncol (2011) 29(Suppl 15):abstr3502.
121. Lee MN, Tseng RC, Hsu HS, Chen JY, Tzao C, Ho WL, et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res (2007) 13(3):832-8. doi:10.1158/1078-0432.CCR-05-2694
122. Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, et al. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol (2011) 224(4):564-74. doi:10.1002/path.2925
123. Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) (2013). Available from: www.clinicaltrials.gov
124. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 4(4):307-20. doi:10.1038/nrd1691
125. Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis (2013) 34(4):739-49. doi:10.1093/carcin/bgs393
126. Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle (2013) 12(6):877-83. doi:10.4161/cc.24034
127. Campelo RB, Felip E, Massuti B, Majem M, Carcereny E, Cardenal F, et al. Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell-lung cancer (NSCLC) (NCT 01513174/GECP-GOAL). J Clin Oncol (2013) 31(Suppl):abstr2581.
128. Olaparib Dose Escalating Trial and Concurrent Radiotherapy With or Without Cisplatin in Locally Advanced NSCLC (2012). Available from: www.clinicaltrials.gov
129. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 448(7153):595-9. doi:10.1038/nature06024
130. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res (2012) 72(7):1608-13. doi:10.1158/0008-5472.CAN-11-3648
131. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 483(7391):570-5. doi:10.1038/nature11005
132. Study of BMN 673, a PARP Inhibitor, in Patients with Advanced or Solid Tumors (2013). Available from: www.clinicaltrials.gov
133. Olaparib in Adults with Recurrent/Metastatic Ewing's Sarcoma (2012). Available from: www.clinicaltrials.gov
134. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADPribose)polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 27(16):2705-11. doi:10.1200/JCO.2008.19.7681
135. Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci (2011) 102(4):663-9. doi:10.1111/j.1349-7006.2010.01840
136. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 29(22):3008-15. doi:10.1200/JCO.2010.34.2980
137. Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors - three and counting. Cancer Discov (2013) 3(1):20-3. doi:10.1158/2159-8290
138. Montoni A, Robu M, Pouliot E, Shah GM. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol (2013) 4:18. doi:10.3389/fphar.2013.00018
139. Ang JE, Gourley C, Powell B, High H, Shapira-Frommer R, Castonguay V, et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of poly(ADP-ribose) polymerase inhibitor resistance: a multi-institutional study. Clin Cancer Res (2013) 19(19):5485-93. doi:10.1158/1078-0432